A Boston-area biopharmaceutical firm has submitted a biologics license application to the FDA for its investigational, fully ...
Biogen BIIB and Japan-based partner, Eisai, announced an update regarding the regulatory review of an application seeking the ...
We recently compiled a list of the 12 Best S&P 500 Stocks to Invest in According to Analysts. In this article, we are going to take a look at where Biogen Inc.
January started the year off strong, with several business updates, long-term clinical trial results on multiple biosimilars, ...
Biogen Inc. closed 41.60% below its 52-week high of $246.44, which the company achieved on February 7th.
Recent health news highlights include a review of the safety of Alzheimer's drug Leqembi, legal charges against a New York ...
Biogen’s effort to buy Sage against the board’s wishes and a long-time effort by investor Alcorn to scuttle Aurion’s IPO ...
The FDA approved Avtozma, a tocilizumab biosimilar developed by Celltrion, for the treatment of several rheumatic conditions.
Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. | Among those ...
The European Commission has requested its medicines regulator to consider safety information on Eisai and Biogen's ...
European Union regulators will review new information relating to the safety of Eisai Co.’s and Biogen Inc.’s medicine for ...
Biogen and Eisai said they believe that EC's requests can be addressed with existing information, and that no new safety signals have been identified for Leqembi. The U.S. Food and Drug Administration ...